Serum cytokine profiling and enrichment analysis reveal the involvement of immunological and inflammatory pathways in stable patients with chronic obstructive pulmonary disease

International Journal of COPD

Volumn 9, Issue , 2014, Pages 759-773

  Bade, Geetanjali ^a   Khan, Meraj Alam ^b   Srivastava, Akhilesh Kumar ^a   Khare, Parul ^a   Solaiappan, Krishna Kumar ^a   Guleria, Randeep ^a   Palaniyar, Nades ^b   Talwar, Anjana ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Bio plex assay; Biomarkers; COPD; Networking; Pathways

Indexed keywords

BIOLOGICAL MARKER; CUTANEOUS T CELL ATTRACTING CHEMOKINE; CYTOKINE; EOTAXIN; INTERLEUKIN 16; INTERLEUKIN 6; SCATTER FACTOR; STEM CELL FACTOR; AUTACOID;

ADULT; AGED; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DYSPNEA; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNE RESPONSE; INFLAMMATION; OXYGEN CONSUMPTION; PROGNOSIS; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SMOKING; BLOOD; CASE CONTROL STUDY; FEMALE; IMMUNOLOGY; LUNG; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROTEIN MICROARRAY; PROTEIN PROTEIN INTERACTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR; SIGNAL TRANSDUCTION; SPIROMETRY; VITAL CAPACITY;

AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INFLAMMATION MEDIATORS; LUNG; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN ARRAY ANALYSIS; PROTEIN INTERACTION MAPS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SIGNAL TRANSDUCTION; SMOKING; SPIROMETRY; VITAL CAPACITY;

EID: 84907333189     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S61347     Document Type: Article

References (49)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
2. Pallasaho P, Kainu A, Sovijärvi A, Lindqvist A, Piirilä PL. Combined effect of smoking and occupational exposure to dusts, gases or fumes on the incidence of COPD. COPD. 2014;11(1):88-95.
3. Moermans C, Heinen V, Nguyen M, et al. Local and systemic cellular inflammation and cytokine release in chronic obstructive pulmonary disease. Cytokine. 2011;56(2):298-304.
4. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165-1185.
5. Agustí A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should). Proc Am Thorac Soc. 2007;4(7):522-525.
6. Aggarwal AN, Gupta D, Agarwal R, Jindal SK. Comparison of the lower confidence limit to the fixed-percentage method for assessing airway obstruction in routine clinical practice. Respir Care. 2011;56(11): 1778-1784.
7. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002;121(5):1434-1440.
8. Aaron SD, Vandemheen KL, Ramsay T, et al. Multi analyte profiling and variability of inflammatory markers in blood and induced sputum in patients with stable COPD. Respir Res. 2010;11:41.
9. Franciosi LG, Page CP, Celli BR, et al. Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2006;19(3):189-199.
10. Lu Y, Feng L, Feng L, Nyunt MS, Yap KB, Ng TP. Systemic inflammation, depression and obstructive pulmonary function: a population-based study. Respir Res. 2013;14:53.
11. Barnes PJ. The cytokine network in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2009;41(6):631-638.
12. Lee JS, Rosengart MR, Kondragunta V, et al. Inverse association of plasma IL-13 and inflammatory chemokines with lung function impairment in stable COPD: a cross-sectional cohort study. Respir Res. 2007;8:64.
13. Esteban C, Quintana JM, Egurrola M, et al. Classifying the severity of COPD: are the new severity scales better than the old? Int J Tuberc Lung Dis. 2009;13(6):783-790.
14. Miller MR, Hankinson J, Brusasco V, et al; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26(2):319-338.
15. Cao C, Wang R, Wang J, Bunjhoo H, Xu Y, Xiong W. Body mass index and mortality in chronic obstructive pulmonary disease: a meta-analysis. PLoS One. 2012;7(8):e43892.
16. Dal Corso S, de Camargo AA, Izbicki M, Malaguti C, Nery LE. A symptom-limited incremental step test determines maximum physiological responses in patients with chronic obstructive pulmonary disease. Respir Med. 2013;107(12):1993-1999.
17. Rabe KF. Improving dyspnea in chronic obstructive pulmonary disease: optimal treatment strategies. Proc Am Thorac Soc. 2006;3(3): 270-275.
18. Ferris BG. Epidemiology Standardization Project (American Thoracic Society). Am Rev Respir Dis. 1978;118(6 Pt 2):1-120.
19. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev. 2004;56(4):515-548.
20. de Jager W, Rijkers GT. Solid-phase and bead-based cytokine immunoassay: a comparison. Methods. 2006;38(4):294-303.
21. Hayakawa I, Hasegawa M, Matsushita T, et al. Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis. Rheumatology (Oxford). 2005;44(7):873-878.
22. Menzies-Gow A, Ying S, Sabroe I, et al. Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. J Immunol. 2002;169(5):2712-2718.
23. Zhang YW, Su Y, Volpert OV, Vande Woude GF. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A. 2003;100(22):12718-12723.
24. Rincon M. Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol. 2012;33(11):571-577.
25. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med. 2009;360(23):2445-2454.
26. Al-Muhsen SZ, Shablovsky G, Olivenstein R, Mazer B, Hamid Q. The expression of stem cell factor and c-kit receptor in human asthmatic airways. Clin Exp Allergy. 2004;34(6):911-916.
27. Traves SL, Culpitt SV, Russell RE, Barnes PJ, Donnelly LE. Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD. Thorax. 2002;57(7):590-595.
28. Di Stefano A, Caramori G, Gnemmi I, et al. Association of increased CCL5 and CXCL7 chemokine expression with neutrophil activation in severe stable COPD. Thorax. 2009;64(11):968-975.
29. Hennighausen L, Robinson GW. Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes Dev. 2008;22(6):711-721.
30. Kagami S, Sugaya M, Minatani Y, et al. Elevated serum CTACK/CCL27 levels in CTCL. J Invest Dermatol. 2006;126(5):1189-1191.
31. Pinto-Plata V, Toso J, Lee K, et al. Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax. 2007;62(7):595-601.
32. Barbu C, Iordache M, Man MG. Inflammation in COPD: pathogenesis, local and systemic effects. Rom J Morphol Embryol. 2011;52(1): 21-27.
33. D'Armiento JM, Scharf SM, Roth MD, et al. Eosinophil and T cell markers predict functional decline in COPD patients. Respir Res. 2009;10:113.
34. Krisiukeniene A, Babusyte A, Stravinskaite K, Lotvall J, Sakalauskas R, Sitkauskiene B. Smoking affects eotaxin levels in asthma patients. J Asthma. 2009;46(5):470-476.
35. Crestani B, Marchand-Adam S, Quesnel C, et al. Hepatocyte growth factor and lung fibrosis. Proc Am Thorac Soc. 2012;9(3):158-163.
36. Ware LB, Matthay MA. Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair. Am J Physiol Lung Cell Mol Physiol. 2002;282(5):L924-L940.
37. Mason RJ. Hepatocyte growth factor: the key to alveolar septation? Am J Respir Cell Mol Biol. 2002;26(5):517-520.
38. Miyazawa K, Kitamura A, Kitamura N. Structural organization and the transcription initiation site of the human hepatocyte growth factor gene. Biochemistry. 1991;30(38):9170-9176.
39. Debigaré R, Marquis K, Côté CH, et al. Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest. 2003;124(1):83-89.
40. Aldonyte R, Jansson L, Piitulainen E, Janciauskiene S. Circulating monocytes from healthy individuals and COPD patients. Respir Res. 2003;4:11.
41. Pinto-Plata V, Casanova C, Müllerova H, et al. Inflammatory and repair serum biomarker pattern: association to clinical outcomes in COPD. Respir Res. 2012;13:71.
42. Berlin AA, Lincoln P, Tomkinson A, Lukacs NW. Inhibition of stem cell factor reduces pulmonary cytokine levels during allergic airway responses. Clin Exp Immunol. 2004;136(1):15-20.
43. Gagari E, Rand MK, Tayari L, et al. Expression of stem cell factor and its receptor, c-kit, in human oral mesenchymal cells. Eur J Oral Sci. 2006;114(5):409-415.
44. Dolgachev VA, Ullenbruch MR, Lukacs NW, Phan SH. Role of stem cell factor and bone marrow-derived fibroblasts in airway remodeling. Am J Pathol. 2009;174(2):390-400.
45. Ding L, Dolgachev V, Wu Z, et al. Essential role of stem cell factor-c-Kit signalling pathway in bleomycin-induced pulmonary fibrosis. J Pathol. 2013;230(2):205-214.
46. Costa C, Rufino R, Traves SL, et al. CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. Chest. 2008;133(1): 26-33.
47. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008;118(11):3546-3556.
48. Agustí A, Edwards LD, Rennard SI, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7(5): e37483.
49. Zhang W, Case S, Bowler RP, Martin RJ, Jiang D, Chu HW. Cigarette smoke modulates PGE(2) and host defence against Moraxella catarrhalis infection in human airway epithelial cells. Respirology. 2011;16(3):508-516.